Answers are grounded in this paper and cite their sources.
Adoptive T-cell immunotherapy is one of the targeted immunological methods that have received widespread use in the treatment of oncological diseases. The most used cell platform is CD8+ cytotoxic lymphocytes, in addition to CD4+ and NK cells. The method has the specificity of monoclonal antibodies and minimal side effects. Both cytotoxic T-cell (CTL) and cells containing the chimeric antigen receptor (CAR)-receptor are used. Immunotherapy cells can be obtained from both the patient (autotransplantation) and the donor (allotransplantation). Attempts are being made to create T-cells that do not require HLA-matching and are not taken from the patient so that they can be simpler and cheaper to use. Over time, the scope of application of cytotoxic T cells in the treatment of not only oncological but virus-associated diseases has been expanding. However, the methodology still does not have standard generally accepted protocols, and their development is a big task for the future.
No takes yet. Share an insight, caveat, or question.
Sofia Iakushina (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: